Allscripts (MDRX) PT Raised to $15 at Piper Jaffray
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst Sean Wieland reiterated a Neutral rating but bumped his price target on Allscripts (NASDAQ: MDRX) to $15.00 (from $12.00) following record bookings driven by OptumCare win.
Wieland commented, "Allscripts beat bookings with the announcement of a win at OptumCare, a division of OptumHealth, and is the largest ambulatory deal in the company's History. With this deal in the bag, it was a very solid quarter. We are sticking with our 20x target multiple, however rolling it forward to 2017 estimates, and raising our price target to $15."
Shares of Allscripts closed at $14.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Cuts Price Target on Polaris Industries (PII) Following 3Q Report
- Wedbush Raises price Target on NCR Corp. (NCR) Following 3Q; Reiterates Neutral
- Graphic Packaging (GPK) PT, Estimates Trimmed at Jefferies Post Q3
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesPiper Jaffray, Sean Wieland
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!